CTLA4 and Familial prostate cancer: These studies provide evidence that treatment with anti-CTLA-4 mAbs is generally well tolerated and capable of inducing objective tumor responses in patients with prostate cancer, renal cell carcinoma, melanoma, and lymphoma [13–17].